Oregovomab: Difference between revisions
Content deleted Content added
m Reverted 1 edit by 213.106.248.101 identified as vandalism to last revision by Aztec Master. using TWINKLE |
Anypodetos (talk | contribs) No ATC code |
||
| Line 5: | Line 5: | ||
| target = [[CA125]] |
| target = [[CA125]] |
||
| CAS_number = 213327-37-8 |
| CAS_number = 213327-37-8 |
||
| ATC_prefix = |
| ATC_prefix = none |
||
| ATC_suffix = |
| ATC_suffix = |
||
| ATC_supplemental = |
| ATC_supplemental = |
||
Revision as of 11:27, 31 July 2009
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Source | Mouse |
| Target | CA125 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| Chemical and physical data | |
| Molar mass | 150,000 Daltons |
Oregovomab (marketed under the trade name OvaRex) is a mouse monoclonal antibody it binds to the antigen CA125, a carbohydrate antigen.[1]
This drug was developed by AltaRex Corp.
References
- ^ STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL - OREGOVOMAB, American Medical Association.
 | This monoclonal antibody–related article is a stub. You can help Wikipedia by expanding it. |